Abbott Laboratories (ABT) Financial Ratios
30 years of historical data (1995–2024) · Healthcare · Medical - Devices
EV/EBITDA
↓
15.70
↓-24% vs avg
5yr avg: 20.67
30Y Low4.9·High24.2
P/FCF
↓
23.61
↓-25% vs avg
5yr avg: 31.46
30Y Low4.6·High38.1
P/B Ratio
↓
3.15
↓-42% vs avg
5yr avg: 5.45
30Y Low1.6·High7.0
ROE
↑
30.9%
↓+55% vs avg
5yr avg: 19.9%
30Y Low2%·High44%
Debt/EBITDA
↓
1.52
↓-11% vs avg
5yr avg: 1.70
30Y Low0.4·High5.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ABT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Abbott Laboratories trades at 11.3x earnings, 64% below its 5-year average of 31.2x, sitting at the 41st percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 49%. On a free-cash-flow basis, the stock trades at 23.6x P/FCF, 25% below the 5-year average of 31.5x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $150.0B | $197.7B | $192.5B | $193.7B | $251.8B | $195.5B | $154.7B | $128.0B | $99.8B | $57.0B | $67.6B |
| Enterprise Value | $157.6B | $205.4B | $201.5B | $201.7B | $261.2B | $208.6B | $169.9B | $143.7B | $118.3B | $60.3B | $71.6B |
| P/E Ratio → | 11.29 | 14.80 | 33.66 | 28.08 | 35.72 | 43.80 | 42.17 | 53.98 | 211.37 | 40.86 | 15.28 |
| P/S Ratio | 3.57 | 4.71 | 4.80 | 4.44 | 5.85 | 5.65 | 4.85 | 4.19 | 3.64 | 2.73 | 3.31 |
| P/B Ratio | 3.15 | 4.13 | 4.96 | 5.25 | 6.99 | 5.93 | 4.94 | 4.17 | 3.21 | 2.75 | 3.17 |
| P/FCF | 23.61 | 31.13 | 38.05 | 24.82 | 29.11 | 34.16 | 34.39 | 26.10 | 22.51 | 27.36 | 36.44 |
| P/OCF | 17.52 | 23.10 | 26.51 | 20.21 | 23.90 | 24.75 | 25.21 | 20.32 | 17.92 | 17.78 | 22.80 |
P/E links to full P/E history page with 30-year chart
ABT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Abbott Laboratories's enterprise value stands at 15.7x EBITDA, 24% below its 5-year average of 20.7x. The Healthcare sector median is 14.1x, placing the stock at a 11% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.90 | 5.02 | 4.62 | 6.06 | 6.03 | 5.33 | 4.70 | 4.32 | 2.89 | 3.51 |
| EV / EBITDA | 15.70 | 20.45 | 20.82 | 17.35 | 20.51 | 24.21 | 22.35 | 20.18 | 23.70 | 13.11 | 16.20 |
| EV / EBIT | 23.10 | 26.97 | 27.37 | 23.40 | 30.30 | 36.75 | 34.72 | 39.91 | 38.04 | 35.15 | 21.31 |
| EV / FCF | — | 32.34 | 39.83 | 25.85 | 30.21 | 36.44 | 37.78 | 29.30 | 26.68 | 28.99 | 38.60 |
ABT Profitability
Margins and return-on-capital ratios measuring operating efficiency
Abbott Laboratories earns an operating margin of 16.3%. Operating margins have compressed from 19.2% to 16.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. Return on equity of 30.9% is exceptionally high. ROIC of 9.9% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 50.8% | 50.8% | 50.0% | 51.1% | 53.9% | 50.2% | 52.3% | 51.7% | 47.7% | 53.9% | 53.7% |
| Operating Margin | 16.3% | 16.3% | 16.0% | 19.2% | 21.4% | 15.3% | 14.4% | 12.6% | 7.2% | 15.6% | 14.5% |
| Net Profit Margin | 31.9% | 31.9% | 14.3% | 15.9% | 16.4% | 13.0% | 11.6% | 7.7% | 1.7% | 6.7% | 21.7% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 30.9% | 30.9% | 15.1% | 19.0% | 20.5% | 14.0% | 11.9% | 7.7% | 1.8% | 6.7% | 20.6% |
| ROA | 17.3% | 17.3% | 7.8% | 9.3% | 9.6% | 6.4% | 5.5% | 3.3% | 0.7% | 2.8% | 10.1% |
| ROIC | 9.9% | 9.9% | 10.4% | 13.9% | 15.1% | 8.6% | 7.4% | 6.0% | 4.0% | 9.9% | 8.7% |
| ROCE | 10.8% | 10.8% | 10.9% | 13.8% | 15.0% | 9.0% | 8.0% | 6.1% | 3.4% | 7.8% | 8.7% |
ABT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Abbott Laboratories carries a Debt/EBITDA ratio of 1.5x, which is manageable (53% below the sector average of 3.3x). Net debt stands at $7.7B ($15.3B total debt minus $7.6B cash). Interest coverage of 11.3x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.32 | 0.32 | 0.41 | 0.49 | 0.53 | 0.60 | 0.61 | 0.64 | 0.90 | 1.06 | 0.42 |
| Debt / EBITDA | 1.52 | 1.52 | 1.64 | 1.54 | 1.51 | 2.31 | 2.51 | 2.75 | 5.59 | 4.78 | 2.04 |
| Net Debt / Equity | — | 0.16 | 0.23 | 0.22 | 0.26 | 0.40 | 0.49 | 0.51 | 0.60 | 0.16 | 0.19 |
| Net Debt / EBITDA | 0.76 | 0.76 | 0.93 | 0.69 | 0.74 | 1.51 | 2.00 | 2.21 | 3.71 | 0.74 | 0.90 |
| Debt / FCF | — | 1.21 | 1.77 | 1.03 | 1.09 | 2.28 | 3.39 | 3.20 | 4.18 | 1.63 | 2.16 |
| Interest Coverage | 11.32 | 11.32 | 9.22 | 26.55 | 22.44 | 7.47 | 5.61 | 5.27 | 2.24 | 10.69 | 16.57 |
ABT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.67x means Abbott Laboratories can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 1.23x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.67 | 1.67 | 1.64 | 1.63 | 1.85 | 1.72 | 1.44 | 1.62 | 2.26 | 4.02 | 1.54 |
| Quick Ratio | 1.23 | 1.23 | 1.16 | 1.23 | 1.46 | 1.30 | 1.04 | 1.20 | 1.86 | 3.65 | 1.26 |
| Cash Ratio | 0.56 | 0.56 | 0.53 | 0.66 | 0.78 | 0.60 | 0.38 | 0.45 | 1.08 | 2.82 | 0.67 |
| Asset Turnover | — | 0.52 | 0.55 | 0.59 | 0.57 | 0.48 | 0.47 | 0.46 | 0.36 | 0.38 | 0.46 |
| Inventory Turnover | 3.33 | 3.33 | 3.06 | 3.46 | 3.85 | 3.44 | 3.52 | 3.89 | 3.98 | 3.95 | 3.63 |
| Days Sales Outstanding | — | 60.25 | 59.74 | 51.99 | 54.97 | 67.65 | 62.07 | 61.86 | 69.95 | 56.85 | 61.14 |
ABT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Abbott Laboratories returns 3.4% to shareholders annually — split between a 2.5% dividend yield and 0.9% buyback yield. The payout ratio of 28.6% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 8.9% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.5% | 1.9% | 1.8% | 1.7% | 1.3% | 1.3% | 1.5% | 1.5% | 1.9% | 2.7% | 2.1% |
| Payout Ratio | 28.6% | 28.6% | 62.1% | 47.7% | 45.3% | 57.0% | 61.6% | 83.4% | 387.6% | 109.9% | 32.6% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 8.9% | 6.8% | 3.0% | 3.6% | 2.8% | 2.3% | 2.4% | 1.9% | 0.5% | 2.4% | 6.5% |
| FCF Yield | 4.2% | 3.2% | 2.6% | 4.0% | 3.4% | 2.9% | 2.9% | 3.8% | 4.4% | 3.7% | 2.7% |
| Buyback Yield | 0.9% | 0.7% | 0.6% | 2.0% | 0.9% | 0.2% | 0.5% | 0.2% | 0.8% | 0.9% | 3.3% |
| Total Shareholder Yield | 3.4% | 2.6% | 2.5% | 3.7% | 2.2% | 1.5% | 1.9% | 1.7% | 2.7% | 3.6% | 5.4% |
| Shares Outstanding | — | $1.7B | $1.7B | $1.8B | $1.8B | $1.8B | $1.8B | $1.8B | $1.7B | $1.5B | $1.5B |
Peer Comparison
Compare ABT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ABTYou | $150B | 11.3 | 15.7 | 23.6 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 MDT | $99B | 21.5 | 14.3 | 19.2 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 BSX | $83B | 28.9 | 25.1 | 22.8 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 BDX | $52B | 24.8 | 14.0 | 19.6 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
 BAX | $9B | -9.7 | 25.0 | 27.1 | 30.1% | -2.7% | -14.6% | -1.4% | 14.9 |
 EW | $48B | 45.5 | 25.5 | 35.9 | 78.1% | 27.0% | 10.5% | 15.5% | 0.4 |
 SYK | $112B | 34.8 | 20.2 | 26.1 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 DHR | $124B | 34.7 | 18.1 | 23.5 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 TMO | $176B | 26.7 | 19.0 | 27.9 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 IQV | $30B | 22.5 | 12.9 | 14.6 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Full ABT Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ABT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ABT vs MDT
Side-by-side business, growth, and profitability comparison vs Medtronic plc.
Start ComparisonABT — Frequently Asked Questions
Quick answers to the most common questions about buying ABT stock.
What is Abbott Laboratories's P/E ratio?
Abbott Laboratories's current P/E ratio is 11.3x. The historical average is 19.6x. This places it at the 41th percentile of its historical range.
What is Abbott Laboratories's EV/EBITDA?
Abbott Laboratories's current EV/EBITDA is 15.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 12.4x.
What is Abbott Laboratories's ROE?
Abbott Laboratories's return on equity (ROE) is 30.9%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 22.6%.
Is ABT stock overvalued?
Based on historical data, Abbott Laboratories is trading at a P/E of 11.3x. This is at the 41th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Abbott Laboratories's dividend yield?
Abbott Laboratories's current dividend yield is 2.54% with a payout ratio of 28.6%.
What are Abbott Laboratories's profit margins?
Abbott Laboratories has 50.8% gross margin and 16.3% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Abbott Laboratories have?
Abbott Laboratories's Debt/EBITDA ratio is 1.5x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.